These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 27956204)

  • 21. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
    Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
    Blinova K; Dang Q; Millard D; Smith G; Pierson J; Guo L; Brock M; Lu HR; Kraushaar U; Zeng H; Shi H; Zhang X; Sawada K; Osada T; Kanda Y; Sekino Y; Pang L; Feaster TK; Kettenhofen R; Stockbridge N; Strauss DG; Gintant G
    Cell Rep; 2018 Sep; 24(13):3582-3592. PubMed ID: 30257217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes.
    Asakura K; Hayashi S; Ojima A; Taniguchi T; Miyamoto N; Nakamori C; Nagasawa C; Kitamura T; Osada T; Honda Y; Kasai C; Ando H; Kanda Y; Sekino Y; Sawada K
    J Pharmacol Toxicol Methods; 2015; 75():17-26. PubMed ID: 25910965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of gentamicin and penicillin/streptomycin on the electrophysiology of human induced pluripotent stem cell-derived cardiomyocytes in manual patch clamp and multi-electrode array system.
    Hyun SW; Kim BR; Lin D; Hyun SA; Yoon SS; Seo JW
    J Pharmacol Toxicol Methods; 2018; 91():1-6. PubMed ID: 29288713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system.
    Kanda Y; Yamazaki D; Kurokawa J; Inutsuka T; Sekino Y
    J Pharmacol Toxicol Methods; 2016; 81():196-200. PubMed ID: 27369811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
    Bai S; Pei J; Chen K; Zhao Y; Cao H; Tian L; Ma Y; Dong H
    SLAS Discov; 2021 Mar; 26(3):364-372. PubMed ID: 32914673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proarrhythmia Risk Assessment Using Electro-Mechanical Window in Human iPS Cell-Derived Cardiomyocytes.
    Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
    Biol Pharm Bull; 2022; 45(7):940-947. PubMed ID: 35786601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
    Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Action potential-based MEA platform for in vitro screening of drug-induced cardiotoxicity using human iPSCs and rat neonatal myocytes.
    Jans D; Callewaert G; Krylychkina O; Hoffman L; Gullo F; Prodanov D; Braeken D
    J Pharmacol Toxicol Methods; 2017 Sep; 87():48-52. PubMed ID: 28549786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico assessment of the effects of various compounds in MEA/hiPSC-CM assays: Modeling and numerical simulations.
    Abbate E; Boulakia M; Coudière Y; Gerbeau JF; Zitoun P; Zemzemi N
    J Pharmacol Toxicol Methods; 2018; 89():59-72. PubMed ID: 29066291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks.
    Sharifi M; Buzatu D; Harris S; Wilkes J
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):497. PubMed ID: 29297274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Tanaka K; Takahashi E; Miyamoto K; Morimura K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Shinozawa T; Saito F; Kunimatsu T
    Regul Toxicol Pharmacol; 2017 Aug; 88():238-251. PubMed ID: 28634147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.
    Zeng H; Roman MI; Lis E; Lagrutta A; Sannajust F
    J Pharmacol Toxicol Methods; 2016; 81():217-22. PubMed ID: 27222351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology.
    Christophe B; Crumb WJ
    J Pharmacol Toxicol Methods; 2019; 96():15-26. PubMed ID: 30580044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
    Takasuna K; Kazusa K; Hayakawa T
    Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment.
    Asahi Y; Nomura F; Abe Y; Doi M; Sakakura T; Takasuna K; Yasuda K
    Eur J Pharmacol; 2019 Jan; 842():221-230. PubMed ID: 30391349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A deep learning platform to assess drug proarrhythmia risk.
    Serrano R; Feyen DAM; Bruyneel AAN; Hnatiuk AP; Vu MM; Amatya PL; Perea-Gil I; Prado M; Seeger T; Wu JC; Karakikes I; Mercola M
    Cell Stem Cell; 2023 Jan; 30(1):86-95.e4. PubMed ID: 36563695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
    Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
    Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.